Chunling Hu,Steven N. Hart,Rohan Gnanaolivu,Hongyan Huang,Kun Y. Lee,Jie Na,Chi Gao,Jenna Lilyquist,Siddhartha Yadav,Nicholas J. Boddicker,Raed Samara,Josh Klebba,Christine B. Ambrosone,Hoda Anton-Culver,Paul Auer,Elisa V. Bandera,Leslie Bernstein,Kimberly A. Bertrand,Elizabeth S. Burnside,Brian D. Carter,Heather Eliassen,Susan M. Gapstur,Mia Gaudet,Christopher Haiman,James M. Hodge,David J. Hunter,Eric J. Jacobs,Esther M. John,Charles Kooperberg,Allison W. Kurian,Loic Le Marchand,Sara Lindstroem,Tricia Lindstrom,Huiyan Ma,Susan Neuhausen,Polly A. Newcomb,Katie M. O'Brien,Janet E. Olson,Irene M. Ong,Tuya Pal,Julie R. Palmer,Alpa V. Patel,Sonya Reid,Lynn Rosenberg,Dale P. Sandler,Christopher Scott,Rulla Tamimi,Jack A. Taylor,Amy Trentham-Dietz,Celine M. Vachon,Clarice Weinberg,Song Yao,Argyrios Ziogas,Jeffrey N. Weitzel,David E. Goldgar,Susan M. Domchek,Katherine L. Nathanson,Peter Kraft,Eric C. Polley,Fergus J. Couch

Abstract:BackgroundPopulation-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and management in women with inherited pathogenic variants. MethodsIn a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Associations between pathogenic variants in each gene and the risk of breast cancer were assessed. ResultsPathogenic variants in 12 established breast cancer-predisposition genes were detected in 5.03% of case patients and in 1.63% of controls. Pathogenic variants in BRCA1 and BRCA2 were associated with a high risk of breast cancer, with odds ratios of 7.62 (95% confidence interval [CI], 5.33 to 11.27) and 5.23 (95% CI, 4.09 to 6.77), respectively. Pathogenic variants in PALB2 were associated with a moderate risk (odds ratio, 3.83; 95% CI, 2.68 to 5.63). Pathogenic variants in BARD1, RAD51C, and RAD51D were associated with increased risks of estrogen receptor-negative breast cancer and triple-negative breast cancer, whereas pathogenic variants in ATM, CDH1, and CHEK2 were associated with an increased risk of estrogen receptor-positive breast cancer. Pathogenic variants in 16 candidate breast cancer-predisposition genes, including the c.657_661del5 founder pathogenic variant in NBN, were not associated with an increased risk of breast cancer. ConclusionsThis study provides estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known breast cancer-predisposition genes in the U.S. population. These estimates can inform cancer testing and screening and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes. (Funded by the National Institutes of Health and the Breast Cancer Research Foundation.) The results of this large study involving more than 64,500 U.S. women in the general population and 28 genes that have been previously implicated in conferring risk of breast cancer (when variant) have implications for the interpretation of results obtained by multigene panel testing.

Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas

Genomic ascertainment of CHEK2-related cancer predisposition

Germline variant profiling of CHEK2 sequencing variants in breast cancer patients

CHEK2 founder variants and thyroid cancer risk

Germline Mutations in CDH23, Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary Adenomas.

CHEK2 Mutation in Patient with Multiple Endocrine Glands Tumors. Case Report

A Comprehensive Evaluation of CHEK2 Germline Mutations in Men with Prostate Cancer

The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2

Germline CHEK2 mutations in patients with myeloid neoplasms

CHEK2 germline variants identified in familial non-medullary thyroid cancer lead to impaired protein structure and function

Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2 -negative breast cancer patients

Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations

Identification of a Novel CHEK2 Variant and Assessment of Its Contribution to the Risk of Breast Cancer in French Canadian Women

A Population-Based Study of Genes Previously Implicated in Breast Cancer.

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study

CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.

Multiple Rare Variants in High-Risk Pancreatic Cancer-Related Genes May Increase Risk for Pancreatic Cancer in a Subset of Patients with and Without Germline CDKN2A Mutations.

CHEK2 mutations and papillary thyroid cancer: correlation or coincidence?

Gene-Level Associations in Patients with and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer

A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.

CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.